Clinical Trials Logo

Clinical Trial Summary

The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00966251
Study type Interventional
Source CureTech Ltd
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date October 2009
Completion date June 2011

See also
  Status Clinical Trial Phase
Recruiting NCT03614546 - Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma N/A
Not yet recruiting NCT03672305 - Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC Early Phase 1
Not yet recruiting NCT06124001 - Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma Phase 1/Phase 2
Not yet recruiting NCT02956772 - Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients Phase 2
Active, not recruiting NCT01563484 - Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media Phase 2/Phase 3
Not yet recruiting NCT05872841 - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Phase 2
Recruiting NCT05242757 - Clinical Study of MAK Immune Cells in the Treatment of PHC N/A
Completed NCT01828762 - Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy N/A